Indaptus Therapeutics, Inc.
NCM: INDPLive Quote
About Indaptus Therapeutics, Inc.
Healthcare
Biotechnology
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
📊 Fundamental Analysis
Indaptus Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -587.6%, which indicates that capital utilization is currently under pressure.
At a current price of $2.11, INDP currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $1.51 - $19.91).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$229.32M
Trailing P/E
--
Forward P/E
-1.52
Beta (5Y)
0.99
52W High
$19.91
52W Low
$1.51
Avg Volume
51K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App